Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Content from other channels on our network

Egg producer improves efficiency with flexible marking system

Visy announces new insulation to reduce the use of polystyrene

New liquid catalyst to transform chemical manufacturing

Climate Smart Engineering Conference 2025: program announced

Aussie manufacturing conditions improve at fastest pace since 2022

Food industry and goverment repond to US tariff imposition

Getting the right texture: toolkit to help create more appealing food

A message from a sponsor of FoodTech Qld

Matthews' stand offering deep 2D barcoding intel at FoodTech Qld

Aranet supermarket temperature monitoring solution

EPOC Enviro secures patent for PFAS remediation technology

NSW passes legislation to mandate battery recycling

Climate Council rates political parties on climate

Boral secures grant for cement kiln carbon reduction

Vast secures grant to progress SA Solar Fuels project